新浪登录
腾讯登录Cell Transplant：干细胞疗法有望治疗头部和口腔缺陷和损伤
| 导读 | 在首次人类研究中，研究人员发现相比于传统的骨再生治疗方法，利用干细胞再生颅面组织---主要是骨---更快速、更加有效而且侵入性更小。来自美国密歇根大学牙科学院和密歇根口腔健康研究中心的研究人员与Aastrom生物科学公司在一项临床试验中开展合作：这项临床试验涉及24名牙齿拔出之后接受颚骨重建( jawbone reconstruction)的病人。
病人们要么接受实验性组织修复细胞或者传统引... |
在首次人类研究中，研究人员发现相比于传统的骨再生治疗方法，利用干细胞再生颅面组织---主要是骨---更快速、更加有效而且侵入性更小。来自美国密歇根大学牙科学院和密歇根口腔健康研究中心的研究人员与Aastrom生物科学公司在一项临床试验中开展合作：这项临床试验涉及24名牙齿拔出之后接受颚骨重建( jawbone reconstruction)的病人。
病人们要么接受实验性组织修复细胞或者传统引导骨再生疗法治疗。这种组织修复细胞被称作ixmyelocel-T，是由密歇根大学校办企业Aastrom生物科学公司开发的。
<!--more-->
论文第一作者Darnell Kaigler助理教授说，干细胞疗法最适合于颚骨巨大缺损，比如由于创伤、疾病或出生缺陷而导致的巨大缺损。相对于导入人造的外源物质，干细胞疗法的主要优势在于它利用病人自己的细胞再生组织。
实验结果是非常有前景的。在接受实验性细胞疗法治疗后6周和12周之后，参与这项研究的病人接受牙移植(dental implant)。接受组织修复细胞治疗的病人要比接受传统引导骨再生疗法的病人拥有更高的骨密度和能够更快地发生骨修复。此外，当接受牙移植时，参与试验的病人更少需要接受二次骨移植。
用于组织修复细胞治疗的细胞最初是从病人臀部获取的骨髓中抽提出来的。骨髓经过处理之后而允许包括干细胞在内的很多不同细胞生长。这些干细胞然后被植入口腔和颚骨不同区域之中。
Kaigler说，干细胞疗法仍然可能需要5到10年的时间才能被用于治疗口腔和面部损伤和缺陷。研究人员接下来想在更多的病人身上进行更多的涉及更大颅面缺陷的临床试验。
本文编译自<a href="http://www.sciencedaily.com/releases/2012/07/120730170154.htm" target="_blank">Stem Cell Therapy Could Offer New Hope for Defects and Injuries to Head, Mouth</a>
<div id="ztload">
<div> </div>
<div>
<div>
<img src="http://www.bioon.com/biology/UploadFiles/201208/2012080517385220.gif" alt="" width="113" height="149" border="0" />
<a title="" href="http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0691kaigler" target="_blank">doi: 10.3727/096368912X652968</a>
PMC:
PMID:
</div>
<div>
<br/><strong>Stem Cell Therapy for Craniofacial Bone Regeneration: A Randomized, Controlled, Feasibility Trial</strong><br/>
Darnell Kaigler, Giorgio Pagni, Chan Ho Park, Thomas Braun, Lindsay A. Holman, Erica Yi, Susan A. Tarle, Ronnda L. Bartel, William V. Giannobile
Background: Stem cell therapy offers potential in the regeneration of craniofacial bone defects however, has it not been studied clinically. Tissue repair cells (TRCs) isolated from bone marrow represent a mixed stem and progenitor population enriched in CD90 and CD14 positive cells. In this Phase I/II, randomized, controlled, feasibility trial, we investigated TRC cell therapy to reconstruct localized craniofacial bone defects. Methods: 24 patients requiring localized reconstruction of jawbone defects participated in this longitudinal trial. For regenerative therapy, patients were randomized to receive either guided bone regeneration (GBR) or TRC transplantation. 6 or 12 weeks following treatment, clinical and radiographic assessments of bone repair were performed. Bone biopsies were harvested and underwent quantitative micro-computed tomographic (μCT) and bone histomorphometric analyses. Oral implants were installed, subsequently restored and functionally loaded with tooth restorations. Reconstructed sites were assessed for one year following therapy. Results: No study-related, serious adverse events were reported. Following therapy, clinical, radiographic, tomographic, and histological measures demonstrated that TRC therapy accelerated alveolar bone regeneration compared to GBR therapy. Additionally, TRC treatment significantly reduced the need for secondary bone grafting at the time of oral implant placement with a 5-fold decrease in implant bony dehiscence exposure (residual bone defects) as compared to GBR-treated sites (p < 0.01). Conclusions: Transplantation of TRCs for treatment of alveolar bone defects appears safe and accelerates bone regeneration, enabling jawbone reconstruction with oral implants. The results from this trial support expanded studies of TRC therapy in the treatment of craniofacial deformities (ClinicalTrials.gov number CT00755911).
<br/>来源：生物谷
</div>
</div>
</div>
病人们要么接受实验性组织修复细胞或者传统引导骨再生疗法治疗。这种组织修复细胞被称作ixmyelocel-T，是由密歇根大学校办企业Aastrom生物科学公司开发的。
<!--more-->
论文第一作者Darnell Kaigler助理教授说，干细胞疗法最适合于颚骨巨大缺损，比如由于创伤、疾病或出生缺陷而导致的巨大缺损。相对于导入人造的外源物质，干细胞疗法的主要优势在于它利用病人自己的细胞再生组织。
实验结果是非常有前景的。在接受实验性细胞疗法治疗后6周和12周之后，参与这项研究的病人接受牙移植(dental implant)。接受组织修复细胞治疗的病人要比接受传统引导骨再生疗法的病人拥有更高的骨密度和能够更快地发生骨修复。此外，当接受牙移植时，参与试验的病人更少需要接受二次骨移植。
用于组织修复细胞治疗的细胞最初是从病人臀部获取的骨髓中抽提出来的。骨髓经过处理之后而允许包括干细胞在内的很多不同细胞生长。这些干细胞然后被植入口腔和颚骨不同区域之中。
Kaigler说，干细胞疗法仍然可能需要5到10年的时间才能被用于治疗口腔和面部损伤和缺陷。研究人员接下来想在更多的病人身上进行更多的涉及更大颅面缺陷的临床试验。
本文编译自<a href="http://www.sciencedaily.com/releases/2012/07/120730170154.htm" target="_blank">Stem Cell Therapy Could Offer New Hope for Defects and Injuries to Head, Mouth</a>
<div id="ztload">
<div> </div>
<div>
<div>
<img src="http://www.bioon.com/biology/UploadFiles/201208/2012080517385220.gif" alt="" width="113" height="149" border="0" />
<a title="" href="http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0691kaigler" target="_blank">doi: 10.3727/096368912X652968</a>
PMC:
PMID:
</div>
<div>
<br/><strong>Stem Cell Therapy for Craniofacial Bone Regeneration: A Randomized, Controlled, Feasibility Trial</strong><br/>
Darnell Kaigler, Giorgio Pagni, Chan Ho Park, Thomas Braun, Lindsay A. Holman, Erica Yi, Susan A. Tarle, Ronnda L. Bartel, William V. Giannobile
Background: Stem cell therapy offers potential in the regeneration of craniofacial bone defects however, has it not been studied clinically. Tissue repair cells (TRCs) isolated from bone marrow represent a mixed stem and progenitor population enriched in CD90 and CD14 positive cells. In this Phase I/II, randomized, controlled, feasibility trial, we investigated TRC cell therapy to reconstruct localized craniofacial bone defects. Methods: 24 patients requiring localized reconstruction of jawbone defects participated in this longitudinal trial. For regenerative therapy, patients were randomized to receive either guided bone regeneration (GBR) or TRC transplantation. 6 or 12 weeks following treatment, clinical and radiographic assessments of bone repair were performed. Bone biopsies were harvested and underwent quantitative micro-computed tomographic (μCT) and bone histomorphometric analyses. Oral implants were installed, subsequently restored and functionally loaded with tooth restorations. Reconstructed sites were assessed for one year following therapy. Results: No study-related, serious adverse events were reported. Following therapy, clinical, radiographic, tomographic, and histological measures demonstrated that TRC therapy accelerated alveolar bone regeneration compared to GBR therapy. Additionally, TRC treatment significantly reduced the need for secondary bone grafting at the time of oral implant placement with a 5-fold decrease in implant bony dehiscence exposure (residual bone defects) as compared to GBR-treated sites (p < 0.01). Conclusions: Transplantation of TRCs for treatment of alveolar bone defects appears safe and accelerates bone regeneration, enabling jawbone reconstruction with oral implants. The results from this trial support expanded studies of TRC therapy in the treatment of craniofacial deformities (ClinicalTrials.gov number CT00755911).
<br/>来源：生物谷
</div>
</div>
</div>
还没有人评论，赶快抢个沙发